April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Measuring Possible Treatment Effects In Stargardt Disease
Author Affiliations & Notes
  • Elizabeth O. Tegins
    Ophthalmology, The Krieger Eye Institute, Sinai Hospital, Baltimore, Maryland
  • Janet S. Sunness
    Hoover Rehab Low Vision Svc, Greater Baltimore Med Ctr, Baltimore, Maryland
  • Joshua N. Steiner
    Ophthalmology, National Retina Institute, Towson, Maryland
  • Footnotes
    Commercial Relationships  Elizabeth O. Tegins, None; Janet S. Sunness, Acucela, Taligen, Genentech, Pfizer, Novartis, Alcon ReVision, Potentia, Ophthotech, Neurotech,Shire, GSK, Othera, Sucampo, Cell Cure (C); Joshua N. Steiner, None
  • Footnotes
    Support  Reserach to Prevent Blindness (JSS)
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5005. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elizabeth O. Tegins, Janet S. Sunness, Joshua N. Steiner; Measuring Possible Treatment Effects In Stargardt Disease. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5005.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : A number of different treatments for Stargardt disease (STGD) have been proposed, but how to measure a treatment effect remains a difficult problem. Autofluorescence images were analyzed to determine whether there were clearly measurable features, and the degree of concordance between eyes of each patient.

Methods: : The images for each patient were deidentified and coded so that each image had a code that was distinct for each eye of the patient. The images were analyzed for quantifiable features. These features were outlined using Adobe Photoshop, and measured using ImageJ. The features deemed measurable were then compared for the two eyes of each patient.

Results: : Twenty seven patients had adequate autofluorescence images for both eyes. The features used to define lesions were homogeneous dark 64%, homogeneous plus mottled dark 14%, mottled 7%, rings of autofluorescence 14%. The lesions ranged from 0.15 to 28.37 sq mm, with a median of 3 sq mm. The mean difference between eyes was 0.13 sq mm, stdev 1.4. The average absolute difference was 0.84 sq mm. The mean percent difference between eyes was 20%.

Conclusions: : There are features in the imaging of Stargardt disease that are quantifiable in a reproducible manner. These data will help to assess concordance between the two eyes of a patient. Although these features may not correlate directly with visual function, they are measures of progression of disease and may be used as evidence of treatment efficacy.

Keywords: degenerations/dystrophies • macula/fovea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.